News summary

FibroBiologics Reports Third Quarter 2026 Financial Results; Highlights Upcoming Catalysts

Source: PR Newswire • Published: 16 Nov 2026, 21:13

Summarized by Masters of Longevity from PR Newswire.

Company will report initial safety data from a Phase 1/2 diabetic foot ulcer trial.

FibroBiologics Reports Third Quarter 2026 Financial Results; Highlights Upcoming Catalysts
Key Takeaways
  • Initial safety data for CYWC628 is expected mid-December 2026.
  • Interim efficacy data for CYWC628 is anticipated in February 2027.
  • Findings are from a Phase 1/2 trial and are not causal.
Read the full article at PR Newswire ↗

Continue exploring

Recommended MoL Picks

MoL PickApple Brings Longevity to the Wrist. What Will It Change?Apple’s new Health Age, readiness and movement tools bring long-term health into everyday view. The opportunity is turning that information into useful action.MoL PickMelatonin and Heart Failure: What the Evidence Actually ShowsA 2025 study linked melatonin use with heart failure. A 2026 analysis found no significant association. Their different designs explain why the question remains open.MoL PickCan Doctors Be Trained for the Longevity Era?A new global survey suggests that healthy longevity medicine education can change how physicians think and talk about ageing. But the evidence also highlights how much work remains before a rapidly growing field becomes routine clinical care.